[
  {
    "ts": null,
    "headline": "Ireland's 'economic miracle' at risk from tariffs",
    "summary": "The deal between the United States and the European Union may have averted a transatlantic trade war, but worries persist in Ireland where crucial sectors are dependent on US multinationals.But \"higher tariffs than there have been\" will make transatlantic trade \"more expensive and more challenging,\" he added.",
    "url": "https://finnhub.io/api/news?id=911af6025161aa2888b29fa639255f8fa1f429694cfeff1a6653765f0e3232ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753719141,
      "headline": "Ireland's 'economic miracle' at risk from tariffs",
      "id": 136107800,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The deal between the United States and the European Union may have averted a transatlantic trade war, but worries persist in Ireland where crucial sectors are dependent on US multinationals.But \"higher tariffs than there have been\" will make transatlantic trade \"more expensive and more challenging,\" he added.",
      "url": "https://finnhub.io/api/news?id=911af6025161aa2888b29fa639255f8fa1f429694cfeff1a6653765f0e3232ed"
    }
  },
  {
    "ts": null,
    "headline": "Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?",
    "summary": "ABBV's Q2 results are likely to hinge on Skyrizi and Rinvoq growth as Humira declines, with 2025 set for a strong revenue rebound.",
    "url": "https://finnhub.io/api/news?id=d5b48a20b1596483bffcf5b07b056d12b593a767dd165e45fed0992ca0894415",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753715760,
      "headline": "Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?",
      "id": 136108006,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "ABBV's Q2 results are likely to hinge on Skyrizi and Rinvoq growth as Humira declines, with 2025 set for a strong revenue rebound.",
      "url": "https://finnhub.io/api/news?id=d5b48a20b1596483bffcf5b07b056d12b593a767dd165e45fed0992ca0894415"
    }
  },
  {
    "ts": null,
    "headline": "Vascarta Announces Addition of Dr. Janet Loesberg to Leadership Team",
    "summary": "Vascarta Inc. today announced the addition of Janet Loesberg, PharmD, as the company's Fractional Chief Strategy Officer, effective immediately. Dr. Loesberg will be responsible for corporate strategy development, portfolio and pipeline management, strategic communications and fundraising/investor relations. She will report to Dr. Richard Prince, Chairman, CEO & President.",
    "url": "https://finnhub.io/api/news?id=0953d76935b38499b43beb8b972d28c11203f259f620567ec496db2e4557aeba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753714860,
      "headline": "Vascarta Announces Addition of Dr. Janet Loesberg to Leadership Team",
      "id": 136108007,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Vascarta Inc. today announced the addition of Janet Loesberg, PharmD, as the company's Fractional Chief Strategy Officer, effective immediately. Dr. Loesberg will be responsible for corporate strategy development, portfolio and pipeline management, strategic communications and fundraising/investor relations. She will report to Dr. Richard Prince, Chairman, CEO & President.",
      "url": "https://finnhub.io/api/news?id=0953d76935b38499b43beb8b972d28c11203f259f620567ec496db2e4557aeba"
    }
  },
  {
    "ts": null,
    "headline": "Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?",
    "summary": "Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.",
    "url": "https://finnhub.io/api/news?id=9ca3b1de056818c3e854d9f6659e6a4002503f17b5a53c1942d5a76070049dc7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753712880,
      "headline": "Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?",
      "id": 136108008,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.",
      "url": "https://finnhub.io/api/news?id=9ca3b1de056818c3e854d9f6659e6a4002503f17b5a53c1942d5a76070049dc7"
    }
  },
  {
    "ts": null,
    "headline": "J&J’s Ethicon recalls stapler cartridges over issue linked to 1 death",
    "summary": "The FDA said the device can lock, leading to adverse events including surgical delay, bleeding and death.",
    "url": "https://finnhub.io/api/news?id=8129f2d8e9c70b10289a320e9c009eb1934c3f4f9ce9f6dde1609d6f4a289754",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753709700,
      "headline": "J&J’s Ethicon recalls stapler cartridges over issue linked to 1 death",
      "id": 136108009,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The FDA said the device can lock, leading to adverse events including surgical delay, bleeding and death.",
      "url": "https://finnhub.io/api/news?id=8129f2d8e9c70b10289a320e9c009eb1934c3f4f9ce9f6dde1609d6f4a289754"
    }
  },
  {
    "ts": null,
    "headline": "GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval",
    "summary": "GSK's stable dividend and strong portfolio face modest growth amid competition and legal risks.",
    "url": "https://finnhub.io/api/news?id=f2c1ff55466555a16146f2862081ba3107b08e25c2042e9d05eca444184afeb2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753706498,
      "headline": "GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval",
      "id": 136107253,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2177313278/image_2177313278.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "GSK's stable dividend and strong portfolio face modest growth amid competition and legal risks.",
      "url": "https://finnhub.io/api/news?id=f2c1ff55466555a16146f2862081ba3107b08e25c2042e9d05eca444184afeb2"
    }
  },
  {
    "ts": null,
    "headline": "Blockbuster Drugs on Patent Cliffs Research Report 2025 | 2030 Patent Cliff to Be Largest Since 2010, Hitting Blockbusters Like Keytruda, Eliquis, and Darzalex",
    "summary": "Upcoming 2025-2030 patent cliff threatens revenue for major pharma companies as Merck, BMS, and J&J top drugs lose exclusivity. Strategies like M&A, R&D investment, and life cycle management could help sustain growth. Companies like Eli Lilly showcase resilience with a 165% projected revenue boost.Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The \"Blockbuster Drugs on Patent Cliffs\" report has been added to ResearchAndMarkets.com's offering. This report talks about the effect of patent cliffs on blo",
    "url": "https://finnhub.io/api/news?id=5f0ab869d43ff0466ffdd37ff5a622d27778906a5712a9437d57d7affe83531b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753689660,
      "headline": "Blockbuster Drugs on Patent Cliffs Research Report 2025 | 2030 Patent Cliff to Be Largest Since 2010, Hitting Blockbusters Like Keytruda, Eliquis, and Darzalex",
      "id": 136107937,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Upcoming 2025-2030 patent cliff threatens revenue for major pharma companies as Merck, BMS, and J&J top drugs lose exclusivity. Strategies like M&A, R&D investment, and life cycle management could help sustain growth. Companies like Eli Lilly showcase resilience with a 165% projected revenue boost.Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The \"Blockbuster Drugs on Patent Cliffs\" report has been added to ResearchAndMarkets.com's offering. This report talks about the effect of patent cliffs on blo",
      "url": "https://finnhub.io/api/news?id=5f0ab869d43ff0466ffdd37ff5a622d27778906a5712a9437d57d7affe83531b"
    }
  },
  {
    "ts": null,
    "headline": "Guggenheim Lifts PT on Johnson & Johnson (JNJ) to $167 From $164, Keeps a Neutral Rating",
    "summary": "Johnson & Johnson (NYSE:JNJ) is one of the top low volatility healthcare stocks to buy now. On July 17, Guggenheim raised the firm’s price target on Johnson & Johnson (NYSE:JNJ) to $167 from $164, keeping a Neutral rating on the shares. The firm gave the price target upgrade after Johnson & Johnson (NYSE:JNJ) delivered a […]",
    "url": "https://finnhub.io/api/news?id=376a9567acebc752180f56c7177891a7aad9c8d19d05c181d3ccddba5e7fefe3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753682875,
      "headline": "Guggenheim Lifts PT on Johnson & Johnson (JNJ) to $167 From $164, Keeps a Neutral Rating",
      "id": 136108011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) is one of the top low volatility healthcare stocks to buy now. On July 17, Guggenheim raised the firm’s price target on Johnson & Johnson (NYSE:JNJ) to $167 from $164, keeping a Neutral rating on the shares. The firm gave the price target upgrade after Johnson & Johnson (NYSE:JNJ) delivered a […]",
      "url": "https://finnhub.io/api/news?id=376a9567acebc752180f56c7177891a7aad9c8d19d05c181d3ccddba5e7fefe3"
    }
  },
  {
    "ts": null,
    "headline": "TD Cowen Maintains a Hold on Genmab A/S (GMAB)",
    "summary": "Genmab A/S (NASDAQ:GMAB) is one of the most profitable biotech stocks to invest in now. In a report released on July 14, Yaron Werber from TD Cowen maintained a Hold rating on Genmab A/S (NASDAQ:GMAB) without a price target. In other news, Genmab A/S (NASDAQ:GMAB) reported on July 16 that net sales of DARZALEX totaled $3.539 […]",
    "url": "https://finnhub.io/api/news?id=627f262779318800aa6cea383ea8b69a2740741dd8adce93208b43c05d6ed058",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753682872,
      "headline": "TD Cowen Maintains a Hold on Genmab A/S (GMAB)",
      "id": 136108012,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Genmab A/S (NASDAQ:GMAB) is one of the most profitable biotech stocks to invest in now. In a report released on July 14, Yaron Werber from TD Cowen maintained a Hold rating on Genmab A/S (NASDAQ:GMAB) without a price target. In other news, Genmab A/S (NASDAQ:GMAB) reported on July 16 that net sales of DARZALEX totaled $3.539 […]",
      "url": "https://finnhub.io/api/news?id=627f262779318800aa6cea383ea8b69a2740741dd8adce93208b43c05d6ed058"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target",
    "summary": "Johnson & Johnson (NYSE:JNJ) ranks among the best low volatility stocks to buy according to analysts. On July 16, Stifel maintained its Hold rating on Johnson & Johnson (NYSE:JNJ), but increased its price target for the healthcare giant from $155 to $165. The price target increase comes after JNJ revised its outlook, which now predicts […]",
    "url": "https://finnhub.io/api/news?id=f000aad49b40076936ea7391ee8b6803507744a0bffe237d348a1311df3457cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753681355,
      "headline": "Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target",
      "id": 136108013,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) ranks among the best low volatility stocks to buy according to analysts. On July 16, Stifel maintained its Hold rating on Johnson & Johnson (NYSE:JNJ), but increased its price target for the healthcare giant from $155 to $165. The price target increase comes after JNJ revised its outlook, which now predicts […]",
      "url": "https://finnhub.io/api/news?id=f000aad49b40076936ea7391ee8b6803507744a0bffe237d348a1311df3457cf"
    }
  },
  {
    "ts": null,
    "headline": "Best Dividend Aristocrats For August 2025",
    "summary": "Dividend Aristocrats are outperforming SPY in July but still trail year-to-date. Check out my Promising Aristocrats list here.",
    "url": "https://finnhub.io/api/news?id=830665c984684da2b011aea06a74a0926a66a23d46b32622de0a5dbcf64f981a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753679992,
      "headline": "Best Dividend Aristocrats For August 2025",
      "id": 136105728,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2189040496/image_2189040496.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Dividend Aristocrats are outperforming SPY in July but still trail year-to-date. Check out my Promising Aristocrats list here.",
      "url": "https://finnhub.io/api/news?id=830665c984684da2b011aea06a74a0926a66a23d46b32622de0a5dbcf64f981a"
    }
  }
]